Cipla Limited (CIPLA) - Total Assets
Based on the latest financial reports, Cipla Limited (CIPLA) holds total assets worth Rs401.64 Billion INR (≈ $4.34 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Cipla Limited - Total Assets Trend (2004–2025)
This chart illustrates how Cipla Limited's total assets have evolved over time, based on quarterly financial data. Also see Cipla Limited market cap and net worth for the company's overall valuation and market capitalisation.
Cipla Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Cipla Limited's total assets of Rs401.64 Billion consist of 62.3% current assets and 37.7% non-current assets. Review CIPLA total debt and obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs116.70 Million | 1.6% |
| Accounts Receivable | Rs55.06 Billion | 14.7% |
| Inventory | Rs56.42 Billion | 15.1% |
| Property, Plant & Equipment | Rs64.75 Billion | 17.3% |
| Intangible Assets | Rs17.16 Billion | 4.6% |
| Goodwill | Rs32.70 Billion | 8.8% |
Asset Composition Trend (2004–2025)
This chart illustrates how Cipla Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See CIPLA stock price and chart for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cipla Limited's current assets represent 62.3% of total assets in 2025, a decrease from 64.7% in 2004.
- Cash Position: Cash and equivalents constituted 1.6% of total assets in 2025, up from 0.3% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 12.0% of total assets, an increase from 0.0% in 2004.
- Asset Diversification: The largest asset category is property, plant & equipment at 17.3% of total assets.
Cipla Limited Competitors by Total Assets
Key competitors of Cipla Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥31.82 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Neuland Laboratories Limited
NSE:NEULANDLAB
|
India | Rs29.30 Billion |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062
|
China | CN¥17.01 Billion |
Cipla Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.96 | 3.84 | 2.77 |
| Quick Ratio | 2.98 | 2.82 | 1.77 |
| Cash Ratio | 0.13 | 0.17 | 0.00 |
| Working Capital | Rs186.21 Billion | Rs154.90 Billion | Rs87.89 Billion |
Cipla Limited - Advanced Valuation Insights
This section examines the relationship between Cipla Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.28 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | 14.3% |
| Total Assets | Rs373.87 Billion |
| Market Capitalization | $11.80 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Cipla Limited's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Cipla Limited's assets grew by 14.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Cipla Limited (2004–2025)
The table below shows the annual total assets of Cipla Limited from 2004 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs373.87 Billion ≈ $4.04 Billion |
+14.27% |
| 2024-03-31 | Rs327.18 Billion ≈ $3.54 Billion |
+11.05% |
| 2023-03-31 | Rs294.63 Billion ≈ $3.19 Billion |
+8.72% |
| 2022-03-31 | Rs271.01 Billion ≈ $2.93 Billion |
+7.75% |
| 2021-03-31 | Rs251.52 Billion ≈ $2.72 Billion |
+6.29% |
| 2020-03-31 | Rs236.63 Billion ≈ $2.56 Billion |
-1.26% |
| 2019-03-31 | Rs239.63 Billion ≈ $2.59 Billion |
+4.82% |
| 2018-03-31 | Rs228.61 Billion ≈ $2.47 Billion |
+8.67% |
| 2017-03-31 | Rs210.37 Billion ≈ $2.28 Billion |
-0.43% |
| 2016-03-31 | Rs211.28 Billion ≈ $2.28 Billion |
+34.42% |
| 2015-03-31 | Rs157.18 Billion ≈ $1.70 Billion |
+17.27% |
| 2014-03-31 | Rs134.03 Billion ≈ $1.45 Billion |
+14.96% |
| 2013-03-31 | Rs116.59 Billion ≈ $1.26 Billion |
+24.70% |
| 2012-03-31 | Rs93.50 Billion ≈ $1.01 Billion |
+8.76% |
| 2011-03-31 | Rs85.97 Billion ≈ $929.70 Million |
+17.62% |
| 2010-03-31 | Rs73.09 Billion ≈ $790.45 Million |
+6.60% |
| 2009-03-31 | Rs68.57 Billion ≈ $741.53 Million |
+19.61% |
| 2008-03-31 | Rs57.33 Billion ≈ $619.96 Million |
+29.88% |
| 2007-03-31 | Rs44.14 Billion ≈ $477.33 Million |
+27.63% |
| 2006-03-31 | Rs34.58 Billion ≈ $374.01 Million |
+32.39% |
| 2005-03-31 | Rs26.12 Billion ≈ $282.50 Million |
+17.66% |
| 2004-03-31 | Rs22.20 Billion ≈ $240.10 Million |
-- |
About Cipla Limited
Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, suc… Read more